469 related articles for article (PubMed ID: 29684239)
21. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
[TBL] [Abstract][Full Text] [Related]
23. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
25. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
26. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
27. A solid-phase enzyme immunoassay for anti-acetylcholine receptor antibody in myasthenia gravis patients.
Kobayashi N; Sugita H; Terada E; Ghoda A; Okudaira H; Ogita T; Miyamoto T
J Immunol Methods; 1984 Oct; 73(2):267-72. PubMed ID: 6386990
[TBL] [Abstract][Full Text] [Related]
28. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
[TBL] [Abstract][Full Text] [Related]
29. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.
Vincent A; Newsom-Davis J
Clin Exp Immunol; 1982 Aug; 49(2):266-72. PubMed ID: 7127905
[TBL] [Abstract][Full Text] [Related]
30. Anti-AChR-negative myasthenia gravis: clinical and immunological features.
Evoli A; Bartoccioni E; Batocchi AP; Scuderi F; Tonali P
Clin Invest Med; 1989 Apr; 12(2):104-9. PubMed ID: 2706833
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
Jonsson DI; Pirskanen R; Piehl F
Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
35. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
36. [Value of acetylcholine receptor antibodies in myasthenia gravis].
Zeitlhofer J; Maida EM; Mamoli B; Mayr N
Wien Med Wochenschr; 1986 Jul; 136(13):329-32. PubMed ID: 3765651
[TBL] [Abstract][Full Text] [Related]
37. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
[TBL] [Abstract][Full Text] [Related]
38. Acetylcholine receptor antibody in the diagnosis of myasthenia gravis.
Nicholson GA; McLeod JG; Griffiths LR
Med J Aust; 1983 Oct; 2(7):334-7. PubMed ID: 6621466
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension.
Nowak RJ; Breiner A; Bril V; Allen JA; Khan S; Levine T; Jacobs DH; Sahagian G; Siddiqi ZA; Xu J; Macias WL; Benatar M;
Ann Clin Transl Neurol; 2024 Jan; 11(1):194-206. PubMed ID: 38062618
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
